Anti-fake readiness a factor for emerging biotech buyers
Biopharm are increasingly assessing the threat counterfeiting and diversion pose to emerging biotechs when planning an acquisition, according to a white paper.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs